# Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

> **NCT04276597** · PHASE2 · WITHDRAWN · sponsor: **Excel Diagnostics and Nuclear Oncology Center**

## Conditions studied

- Pulmonary Neuroendocrine Neoplasm
- Pheochromocytoma
- Paraganglioma
- Thymus Carcinoid
- Unknown Primary Tumors
- Neuroendocrine Tumors
- Neuroendocrine Skin Carcinoma
- Neuroendocrine Breast Tumor
- Neuroendocrine Carcinoma Metastatic
- Neuroendocrine Neoplasm of Ovary

## Interventions

- **DRUG:** 177Lu-DOTATOC

## Key facts

- **NCT ID:** NCT04276597
- **Lead sponsor:** Excel Diagnostics and Nuclear Oncology Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-03-04
- **Primary completion:** 2021-07-15
- **Final completion:** 2021-07-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No subjects were eligible for the study. The study closed on 07-15-2021.
- **Last updated:** 2023-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04276597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04276597, "Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04276597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*